|
市場調查報告書
風濕性關節炎治療藥的藥品開發
Rheumatoid Arthritis Drug Discoveries: what the future holds
|
風濕性關節炎治療藥的藥品開發 是由出版商Espicom Business Intelligence在2008年03月所出版的。
這份英文市場調查報告書包含Pages: 250 價格從美金1740起跳。
本報告書內容包括：風濕性關節炎的現有治療方法、風濕性關節炎治療藥市場的發展刺激因素・阻礙因素、主要企業・產品、R&D動向等調查分析以及主要企業的介紹。內容綱要摘記如下：
介紹
何謂風濕性關節炎
目前的治療
患者統計
風濕性關節炎市場
主要產品分析
- 非施德丁類抗炎症藥
- 糖皮質類固醇
- 傳統疾病修飾性抗風濕性關節炎藥
- 生物學製劑
風濕性關節炎治療藥的R&D
附錄：企業介紹
圖表
Abstract
The value of the rheumatoid arthritis (RA) market currently stands at
approximately US$11.6 billion and is continuing to grow, driven mainly by the
biologic DMARDs. It is dominated by five major pharma companies: Abbott,
Amgen, Johnson & Johnson, Schering-Plough and Wyeth, which between them market
three of the most successful biologics, the tumour necrosis factor inhibitors
Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab).
Research into new treatments is intense, driven by the need for safer and even
more effective medications with more convenient dosing schedules.
GlaxoSmithKline, Johnson & Johnson, Roche, Schering-Plough and UCB all have
biologics in the late phases of development, while Pfizer is pinning its hopes
on its oral kinase inhibitors, which are currently in Phase II development. As
these new therapies come on board and the market becomes more competitive, the
prospects for RA patients can only improve.
This report provides a complete assessment of the market' s potential
This new management report provides a complete examination of the RA market
and its prospects in the medium term. Packed with analysis and forecasts,
anyone needing to understand the drivers of this fast growing sector need look
no further.
Providing…
- Detailed assessment and 5-year forecasts for current leading products by
value
- A detailed review and assessment of up and coming products
- Unique product assessment and scoring
Major approaches
- Adenosine receptor antagonist
- B-cell targeted therapy
- Cathepsin-S inhibitors
- Chemokine receptor antagonists
- DHODH inhibitors
- Glucocorticoids
- Interleukin inhibitors
- Kinase inhibitors
- Lymphotoxin beta and light pathway inhibitor
- Non-steroidal anti-inflammatory drugs
- RANK ligand inhibitor
- T-cell co-stimulation modulator
- TNF inhibitors
- Traditional disease-modifying anti-rheumatic drugs
Table of Contents
- INTRODUCTION
- WHAT IS RHEUMATOID ARTHRITIS?
- Pathogenesis Of Rheumatoid Arthritis
- Classification Of Rheumatoid Arthritis
- Assessment Of Disease Activity And Response To Treatment
- CURRENT TREATMENT OPTIONS
- Diagnosis of Rheumatoid Arthritis
- Pharmacological Therapy
- Treatment Strategies
- PATIENT STATISTICS
- Incidence and Prevalence
- The Future
- THE RHEUMATOID ARTHRITIS MARKET
- PLAYERS AND PRODUCTS
- Players And Products In 2007
- Players And Products In 2015
- DRUG GROWTH DRIVERS AND DAMPENERS
- ANALYSIS OF CURRENT LEADING PRODUCTS
- NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
- GLUCOCORTICOIDS
- TRADITIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
- BIOLOGICAL AGENTS
- TNF Inhibitors
- Interleukin-1 Receptor Inhibitor
- B-Cell Targeted Therapy
- T-Cell Co-Stimulation Modulator
- RESEARCH AND DEVELOPMENT OF RHEUMATOID ARTHRITIS DRUGS
- LATE-PHASE PROJECTS
- TNF Inhibitors
- Interleukin-6 Receptor Inhibitor
- Interleukin-1 Receptor Inhibitor
- B-Cell Targeted Therapy
- Non-Steroidal Anti-Inflammatory Drugs
- Glucocorticoid
- PHASE II PROJECTS
- Oral Therapies
- Adenosine Receptor Antagonist
- Cathepsin-S Inhibitor
- Chemokine Receptor Antagonists
- DHODH Inhibitor
- Interleukin Inhibitors
- Kinase Inhibitors
- 681323
- 856553
- BMS-582949
- CP-195543
- CP-690550
- INCB18424
- PH-797804
- SCIO-469
- Tamatinib
- VX-702
- T-Cell Co-Stimulation Modulator
- Other Oral Therapies
- 274150
- CH-1504
- CRx-102
- K-832
- PMI-001
- R7277
- Injectable Therapies
- B-Cell Targeted Therapy
- Atacicept
- LymphoStat-B
- TRU-015
- Interleukin Inhibitors
- Lymphotoxin Beta and LIGHT Pathway Inhibitor
- RANK Ligand Inhibitor
- TNF Inhibitor
- Other Injectable Therapies
- PHASEI PROJECTS
- Kinase Inhibitors
- ARRY-438162
- ARRY-797
- MLN0415
- Anti-TNF
- Others
- APPENDIX 1: COMPETITOR RATIO ANALYSIS
- APPENDIX 2: COMPANY PROFILES
- 4SC
- Abbott
- Amgen
- Arana Therapeutics
- AstraZeneca
- Biogen Idec
- Bristol-Myers Squibb
- Can-Fite Biopharma
- Chelsea Therapeutics
- Chugai
- CombinatoRx
- Dainippon Sumitomo Pharma
- Eisai
- Eli Lilly
- Genmab
- GlaxoSmithKline
- Human Genome Sciences
- Johnson & Johnson
- Kowa Pharmaceutical
- Medarex
- Medigene
- Merck KGaA
- Merrimack Pharmaceuticals
- Millennium Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Novartis
- Phytomedics
- Pozen
- Pfizer
- Rigel Pharmaceuticals
- Roche
- sanofi-aventis
- Schering-Plough
- Synta Pharmaceuticals
- Takeda
- Targeted Genetics
- Toyama Chemical
- Trubion
- Wyeth
- Vertex Pharmaceuticals
- APPENDIX 3: GLOSSARY
- APPENDIX 4: SOURCES
- APPENDIX 5: PRODUCT INDEX
INDEX OF TABLES
- Traditional DMARDs used in the treatment of RA
- ACR responses
- Products In Development For The Treatment Of Rheumatoid Arthritis
- Competitor Ratio Analysis Scores
- Six- and 12-month ACR responses for RAPID 1
- Six and 12 month mean mTSS changes from baseline for RAPID 1
- Competitor Ratio Analysis Scores
- Competitor Ratio Analysis Summary
INDEX OF CHARTS
- Synovitis And Joint Destruction In Rheumatoid Arthritis
- Bone Erosion In Untreated Rheumatoid Arthritis
- Current Views On The Pathogenesis Of Rheumatoid Arthritis
- Guidelines For The Management Of Rheumatoid Arthritis
- Global Rheumatoid Arthritis Drug Sales (2007E)
- Rheumatoid Arthritis Market (2007E-2015E)
- Global Market Share of Major Biologic RA Products (2007E)
- Global Market Share Of RA Biologics And Oral Therapies By Sales (2015E)
- Celebrex RA Sales (2008E-2015E)
- Remicade RA Sales (2008E-2015E)
- Humira RA Sales (2008E-2015E)
- Enbrel RA Sales (2008E-2015E)
- Kineret RA Sales (2008E-2015E)
- Rituxan/MabThera RA Sales (2008E-2015E)
- Orencia RA Sales (2008E-2015E)
- Launch Of Biologics In Late-Phase Development To Treat Rheumatoid Arthritis
- Cimzia RA Sales (2008E-2015E)
- Golimumab RA Sales (2009E-2015E)
- The Role Of IL-6 In Inflammation
- Actemra RA Sales (2008E-2015E)
- Ocrelizumab RA sales (2011E-2015E)
- Ofatumumab RA Sales (2010E-2015E)
- CF101 RA Sales (2012E-2015E)
- SC12267 RA Sales (2011E-2015E)
- CP-195543 RA Sales (2012E-2015E)
- CP-690550 RA Sales (2011E-2015E)
- Scio-469 RA Sales (2012E-2015E)
- R788 RA Sales (2011E-2015E)
- RhuDex RA Sales (2012E-2015E)
- Atacicept RA Sales (2011E-2015E)
- LymphoStat-B RA sales (2011E-2015E)
- TRU-015 RA Sales (2011E-2015E)
- AMG 108 RA Sales (2011E-2015E)
- Baminercept RA Sales (2010E-2015E)
- Denosumab RA Sales (2009E-2015E)
|
